Session Details

Morning Session 4 - Virus-Specific T Cells Meet the Experts
Sunday, September 15, 2019 07:00 AM - 08:30 AM
Ballroom A

Lynn O'Donnell, PhD, Ohio State University, James Cancer Hospital Columbus, USA


Virus specific T cell therapies- broadening applicability beyond CMV and EBV
Catherine Bollard, MBChB, MD, Children’s National Medical Center, USA
Learning objectives:
•      Understanding the breadth of T cell therapies targeting viruses
•      Understanding strategies for generating a VST “bank” for third party use
•      Discuss the use of naïve donor sources for VST products

John Barrett, MDGeorge Washington University Hospital, USA
Learning objectives:
•      The diversity of human polyomaviruses and the diseases they cause
•      The normal immune response to the viruses and the effect of immune deficiency on viral reactivation
•      Cell therapies to treat BK Virus, JC virus and Merkel Cell Virus.

Third Party Virus Specific T cells (VSTs): Cincinnati Experience
Michael Grimley, MD, Cincinnati Children's Hospital Medical Center, USA
Learning objectives:
•      Discuss the manufacturing process for Viral Specific T cells (VSTs)
•      Clinical results from the use of third party VSTs
•      Indications for the use of third party VSTs